/NGENF
NGENF Stock - NervGen Pharma Corp.
Healthcare|BiotechnologyOTC
$4.52+0.44%
+$0.02 (+0.44%) • Dec 19
77
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.98
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.89
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $4.97
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NGENF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.47 – $4.57
TARGET (TP)$5.20
STOP LOSS$4.16
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.77
52W High$5.10
52W Low$1.50
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-145,003 | $-115,114 | $-42,626 | $-39,645 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-24,931,994 | $-17,776,710 | $-22,823,637 | $-12,866,453 | $-11,186,775 |
| Net Income | $-24,005,895 | $-22,382,120 | $-20,722,283 | $-12,726,578 | $-11,186,141 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.36 | $-0.38 | $-0.39 | $-0.32 | $-0.35 |
Company Overview
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
NGENFBeat Rate
36%
Last 11 quarters
Avg Surprise
-2.9%
EPS vs Estimate
Beats / Misses
4/6
1 met exactly
Latest EPS
$-0.04
Q4 2025
EPS Surprise History
Q4 23
No data
Q2 24
+45.6%
$-0.03vs$-0.05
Q3 24
-24.4%
$-0.08vs$-0.07
Q4 24
-6.2%
$-0.05vs$-0.05
Q4 24
No data
Q2 25
+33.6%
$-0.04vs$-0.06
Q3 25
-68.6%
$-0.09vs$-0.06
Q4 25
+29.4%
$-0.04vs$-0.06
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q4 2025 | Nov 25, 2025 | $-0.06 | $-0.04 | +29.4% | ✓ BEAT |
Q3 2025 | Aug 27, 2025 | $-0.06 | $-0.09 | -68.6% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.06 | $-0.04 | +33.6% | ✓ BEAT |
Q4 2024 | Dec 31, 2024 | — | $-0.09 | — | — |
Q4 2024 | Nov 14, 2024 | $-0.05 | $-0.05 | -6.2% | ✗ MISS |
Q3 2024 | Aug 22, 2024 | $-0.07 | $-0.08 | -24.4% | ✗ MISS |
Q2 2024 | May 16, 2024 | $-0.05 | $-0.03 | +45.6% | ✓ BEAT |
Q4 2023 | Dec 30, 2023 | — | $-0.11 | — | — |
Q4 2023 | Nov 9, 2023 | — | $-0.05 | — | — |
Q3 2023 | Aug 9, 2023 | — | $-0.06 | — | — |
Q2 2023 | May 15, 2023 | — | $-0.06 | — | — |
Q1 2023 | Feb 27, 2023 | — | $-0.08 | — | — |
Q4 2022 | Nov 14, 2022 | $-0.14 | $-0.08 | +42.9% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-0.11 | $-0.13 | -18.2% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.08 | $-0.11 | -37.5% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | $-0.09 | $-0.09 | 0.0% | = MET |
Q4 2021 | Nov 18, 2021 | $-0.07 | $-0.09 | -28.6% | ✗ MISS |
Q3 2021 | Aug 19, 2021 | — | $-0.06 | — | — |
Q2 2021 | May 20, 2021 | — | $-0.05 | — | — |
Latest News
Loading news...
Frequently Asked Questions about NGENF
What is NGENF's current stock price?
NervGen Pharma Corp. (NGENF) is currently trading at $4.52 per share. The stock has moved +0.44% today.
What is the analyst price target for NGENF?
No analyst price targets are currently available for this stock.
What sector is NervGen Pharma Corp. in?
NervGen Pharma Corp. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is NGENF's market cap?
NervGen Pharma Corp. has a market capitalization of $0.35 billion, making it a small-cap company.
Does NGENF pay dividends?
No, NervGen Pharma Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBRIBF
Brii Biosciences Limited
$0.24
Mkt Cap: $0.2B
BXPHF
Botanix Pharmaceuticals Limited
$0.08
Mkt Cap: $0.2B
CLLKF
BICO Group AB (publ)
$1.97
Mkt Cap: $0.1B
GNFTF
Genfit S.A.
$4.14
Mkt Cap: $0.2B
IPHYF
Innate Pharma S.A.
$2.15
Mkt Cap: $0.2B
JWCTF
JW (Cayman) Therapeutics Co. Ltd
$0.39
Mkt Cap: $0.2B
MLLCF
Molecular Partners AG
$3.50
Mkt Cap: $0.1B
NDTP
NDT Pharmaceuticals Inc.
$1.75
Mkt Cap: $0.3B
SCNLF
Scancell Holdings plc
$0.14
Mkt Cap: $0.1B
SPHDF
Santhera Pharmaceuticals Holding AG
$13.35
Mkt Cap: $0.2B
Explore stocks similar to NGENF for comparison